search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.

Dustin J Flanagan ,
Raheleh Amirkhah ,
David F Vincent ,
Nuray Gunduz ,
Pauline Gentaz ,
Patrizia Cammareri ,
Aoife J McCooey ,
Amy M B McCorry ,
Natalie C Fisher ,
Hayley L Davis ,
Rachel A Ridgway ,
Jeroen Lohuis ,
Joshua D G Leach ,
Rene Jackstadt ,
Kathryn Gilroy ,
Elisa Mariella ,
Colin Nixon ,
William Clark ,
Ann Hedley ,
Elke K Markert ,
Douglas Strathdee ,
Laurent Bartholin ,
Keara L Redmond ,
Emma M Kerr ,
Daniel B Longley ,
Fiona Ginty ,
Sanghee Cho ,
Helen G Coleman ,
Maurice B Loughrey ,
Alberto Bardelli ,
Timothy S Maughan ,
Andrew D Campbell ,
Mark Lawler ,
Simon J Leedham ,
Simon T Barry ,
Gareth J Inman ,
Jacco van Rheenen ,
Philip D Dunne ,
Owen J Sansom

Abstract

The pro-tumourigenic role of epithelial TGFβ signalling in colorectal cancer (CRC) is controversial. Here, we identify a cohort of born to be bad early-stage (T1) colorectal tumours, with aggressive features and a propensity to disseminate early, that are characterised by high epithelial cell-intrinsic TGFβ signalling. In the presence of concurrent Apc and Kras mutations, activation of epithelial TGFβ signalling rampantly accelerates tumourigenesis and share transcriptional signatures with those of the born to be bad T1 human tumours and predicts recurrence in stage II CRC. Mechanistically, epithelial TGFβ signalling induces a growth-promoting EGFR-signalling module that synergises with mutant APC and KRAS to drive MAPK signalling that re-sensitise tumour cells to MEK and/or EGFR inhibitors. Together, we identify epithelial TGFβ signalling both as a determinant of early dissemination and a potential therapeutic vulnerability of CRC's with born to be bad traits.

More about this publication

Nature communications

Volume 13
Issue nr. 1
Pages 7551
Publication date 07-12-2022

Full text links

Publisher website (DOI) 10.1038/s41467-022-35134-3
Europe PubMed Central 36477656
Pubmed 36477656

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.